Novo Nordisk(US:NVO) Xin Lang Cai Jing·2025-11-05 10:13Core Insights - Novo Nordisk has lowered its full-year profit and sales forecasts, marking a challenging start for the new CEO Mike Doustdar amid intense competition in the weight loss drug market [1][2] - The company is experiencing a turbulent period characterized by a significant drop in stock price and slowing sales growth, leading to executive changes and board restructuring [1] Financial Performance - For 2025, Novo Nordisk expects operating profit growth to be between 4% and 7%, down from the previous forecast of 4% to 10% [1] - The company anticipates a sales growth of 8% to 11% for the current year, revised down from 8% to 14% [2] - In Q3, global sales of Wegovy increased by 18% year-on-year, reaching 20.4 billion Danish kroner (approximately 3.21 billion USD), which was below analyst expectations of 20.9 billion Danish kroner [2] - Total sales for the quarter grew by 5% year-on-year to 75 billion Danish kroner (approximately 11.71 billion USD), also falling short of the expected 76.2 billion Danish kroner [2] - Operating profit for the quarter decreased by 30% to 23.7 billion Danish kroner (approximately 3.71 billion USD), again below analyst expectations of 24.6 billion Danish kroner [2] Market Competition - Novo Nordisk faces significant competitive pressure from Eli Lilly and the impact of custom compounded generics that share the same ingredients as branded drugs [2] - The company has warned about the ongoing issue of unsafe and illegal mass compounding of generics, which continues to affect its market position [2]